Fractyl Health GUTS
NASDAQ GUTS
$0.78 +0.10 (+14.54%)
As of: Aug 21, 2026 · 12:10 PM EDT

Fractyl Health (GUTS) Gross Margin (2023 - 2024)

Fractyl Health's (GUTS) quarterly Gross Margin came in at 100.0% in Q4 2024, up 2857.0% YoY from 3.38% in Q1 2024, and up 100.0% on a QoQ basis from 50.0% in Q3 2024.

Fractyl Health (GUTS) Gross Margin (2023 - 2024) Analysis & Trends

Fractyl Health (GUTS) has 2 years of Gross Margin data on file, last reported at 100.0% in Q4 2024.

  • Quarterly Gross Margin rose 2857.0% year-over-year to 100.0% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 46.24% (up 1040.0% YoY) and the FY2024 annual result came in at 46.24%, up 1040.0% from the prior year.
  • Gross Margin improved to 100.0% in Q4 2024, from 50.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2024 to a low of 30.56% in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Vertex Pharmaceuticals 139.66 Bn 131.81 Bn 2.84 Bn 85.33%
2 Regeneron Pharmaceuticals 86.52 Bn 78.52 Bn 3.93 Bn 91.59%
3 Argenx Se 65.30 Bn 60.11 Bn 1.37 Bn 90.43%
4 Moderna 59.18 Bn 54.04 Bn 52.00 Mn 35.86%
5 BeOne Medicines 42.08 Bn 36.98 Bn 1.53 Bn 89.76%
6 Alnylam Pharmaceuticals 31.77 Bn 28.46 Bn 992.69 Mn 76.90%
7 BioNTech SE 28.13 Bn 9.74 Bn 668.28 Mn 63.27%
8 Insmed 27.51 Bn 26.35 Bn 358.27 Mn 84.20%
9 Royalty Pharma 27.16 Bn 26.32 Bn - -
10 Fractyl Health 124.13 Mn 124.13 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 100.00%
Sep 30, 2024 50.00%
Jun 30, 2024 44.19%
Mar 31, 2024 42.42%
Dec 31, 2023 71.43%
Sep 30, 2023 30.56%
Jun 30, 2023 34.72%
Mar 31, 2023 40.00%